详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

19| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Hansoh BioMedical R&D Company [2]Anhui Provincial Cancer Hospital,Hefei,Anhui,China,230031 [3]Fujian Provincial Tumor Hospital,Fujian,Fujian,China,350014 [4]The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army,Fuzhou,Fujian,China,350014 [5]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510000 [6]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,1540000 [7]Tumour Hospital of Anyang city,Anyang,Henan,China,455000 [8]The First Affiliated Hospital of Henan University of Science & Technology,Luoyang,Henan,China,471003 [9]Nanyang Central Hospital,Nanyang,Henan,China,422000 [10]The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,China,453100 [11]Henan Cancer Hospital,Zhengzhou,Henan,China,450003 [12]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052 [13]Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030 [14]Hubei Cancer Hospital,Wuhan,Hubei,China,430079 [15]Nantong Tumor Hospital,Nantong,Jiangsu,China,226300 [16]Jiangyin People's Hospital,Wuxi,Jiangsu,China,214400 [17]Jiangxi Provincial Tumor Hospital,Nanchang,Jiangxi,China,330038 [18]Liaoning Cancer Hospital,Shenyang,Liaoning,China,110000 [19]The First Hospital of China Medical University,Shenyang,Liaoning,China,110002 [20]Affiliated Hospital of Jining Medical University,Jining,Shandong,China,272000 [21]Sichuan Cancer Hospital&Institude, Sichuan Cancer Center,Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China,Chengdu,Sichuan,China,610041 [22]The Affiliated Cancer Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,830011

关键词： Advanced solid tumor Esophageal Carcinoma B7-H3 antibody-drug conjugate (ADC) HS-20093

研究目的：

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.